Emmaus Life Sciences (OTCMKTS:EMMA) Announces Earnings Results

Emmaus Life Sciences (OTCMKTS:EMMA) issued its earnings results on Monday. The company reported ($0.03) EPS for the quarter, Zacks reports.

Emmaus Life Sciences Price Performance

Shares of Emmaus Life Sciences stock opened at $0.02 on Tuesday. The company’s 50 day moving average price is $0.02 and its two-hundred day moving average price is $0.02. The firm has a market capitalization of $989,923.00, a P/E ratio of -0.17 and a beta of 6.11. Emmaus Life Sciences has a fifty-two week low of $0.00 and a fifty-two week high of $0.11.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.